Inclusion Criteria:

- Ability to understand and willingness to sign a written informed consent document

- Histologically confirmed metastatic or unresectable solid tumor

- Results from tumor tissue analysis that show a glutamic acid-for-valine substitution
at amino acid position 600 in the BRAF gene (V600E) or other activating BRAF
mutation, as determined by high-throughput genotyping

- Patients may have received any number of prior systemic treatments for their cancer

- At least one measurable site of disease by CT, according to standard RECIST criteria
1.0

- ECOG performance status 0-1

- Absolute neutrophil count > 1500 per cubic mm

- Platelet count > 100,000 per cubic mm

- Hemoglobin > 9 g/dl

- Serum bilirubin < 1.5 x upper limit of normal

- Serum AST and ALT < 2.5 x upper limit of normal (=< 5 x upper limit of normal, for
liver metastases)

- Serum creatinine < 1.5 x upper limit of normal

- For women of childbearing potential, negative serum pregnancy test and use of
physician-approved method of birth control throughout the study

Exclusion Criteria:

- Estimated life expectancy > 12 weeks

- Patients with melanoma

- Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study
(6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior
to entering the study

- Have not recovered from adverse events due to agents previously administered (CTCAE
v3 grade 1 or baseline)

- Currently receiving other investigational agents

- Known brain metastases, unless treated and stable off of corticosteroids for at least
four weeks

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to AZD6244

- Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior
sorafenib is allowed)

- Uncontrolled intercurrent illness, including but not limited to:

- Clinically significant active infection

- Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac
arrhythmia other than atrial fibrillation

- Psychiatric illness/social situations that would limit compliance with study
requirements

- Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that
would interfere with swallowing or absorbing the study medication

- Pregnant and/or breast-feeding women

- Previous or concurrent malignancy, except for the following circumstances:

- Disease-free for at least three years and deemed by investigator to be at low
risk for recurrence of that malignancy

- Individuals with the following cancers are eligible if diagnosed and treated
within the past 5 years: cervical cancer in situ, and basal cell or squamous
cell carcinoma of the skin)

- History of solid organ transplantation or other condition requiring the use of
immunosuppressive medications

- Uncontrolled hypertension (systolic BP >= 150 or diastolic BP >= 100 that cannot be
controlled with medications)

- A mean left ventricular ejection fraction (LVEF) less than 45%